OHE https://validator.w3.org/feed/docs/rss2.html OHE statement on 2025 Spending Review Can we “Netflix” the Broken Antibiotics Market? OHE Annual Lecture 2022 | Universal Health Coverage: More Than Just Old Wine in a New Bottle? OHE Annual Lecture 2023 | The ECO-nomics of Health in a Shifting Climate: Fostering Well-being, Sustainable Livelihoods, and a Greener Future Insights From 2022 and Emerging Issues in 2023 Vaccines, Antivirals, Lockdowns and COVID: Lessons from the Pandemic The Value of Vaccines and Taskforces Informal Caring Burden in HTA Series: Webinar 1 – What is carer burden and why is it important in HTA? OHE responds to the Trump administration’s Executive Order on Drug Prices Informal Caring Burden in HTA Series: Webinar 2 – How is carer burden captured in HTA, and what are some of the existing challenges? Informal Caring Burden in HTA Series: Webinar 3 – Capturing carer burden in HTA: what is the future? Valuing Vaccines: The Economics of Vaccines & Immunisations Cell & Gene Therapies: Can We Find Innovative Ways to Pay? Supporting Sustainability in the Era of Green Pharmaceuticals Partnerships for Health System Innovation and Improvement OHE at ISPOR Europe 2023 Reimagining Prevention for a Healthier, More Prosperous Society Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care? Insights and Reflections from 2023 The Future of NICE in a Changing HTA Landscape Efficiency and Labour Productivity of Primary Care in England OHE Annual Lecture 2024 | The Preventive Health Revolution: Live Longer, Live Better MFN, Its Global Ripple Effects, and the Role of HTA in the US OHE responds to the NHS Ten Year Plan OHE responds to the 2025 UK Budget Europe’s pharmaceutical policy choices – And what the United States stands to learn OHE to host the Health Economists’ Study Group Summer 2025 New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy Atherosclerotic cardiovascular disease (ASCVD) costs the world $680 billion a year in healthcare – roughly the size of Sweden’s entire economy, new research finds  New OHE model estimates COVID-19 could be associated with costs of £7 billion a year in the UK, without annual autumn vaccinations    New OHE research finds productivity losses from respiratory infections cost UK businesses £44 billion per year The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases New research reveals, in carers’ own words, the multidimensional burden of caring for leukemia patients Our governance and network Bruce Hollingsworth Martin L. Lee Seven reflections on the UK EQ-5D-5L value set – and what comes next Opportunities to Increase Efficiency in Healthcare OHE Salah Ghabri Julia Toth SooChin Yen Ellie Tunnicliffe George Bray How Widely Are QALYs Used in OECD Countries? A Snapshot of International Practices The Trump Administration’s US Drug Pricing Proposal – What will happen next? Does the New CBO Report Change Anything? Two perspectives on perspective Around The World in HTAs: France – Three Core HTA Values Adrian Towse